Doctors choose PPI to replace ranitidine alternative

Surveying 1664 doctors for preference on ranitidine alternative

Favors esomeprazole for PPI, famotidine for H2RA the most

Acid blocking and mucosal protective effects are the most crucial factors

Apparently, healthcare providers are in favor of proton pump inhibitor (PPI), as an alternative to ranitidine after confirmed contamination of carcinogen N-nitrosodimenthylamine (NDMA) in some of ranitidine products.

 

Doctor Ville, an online community exclusive to healthcare providers, recently conducted a survey on 1,664 doctors about alternatives to ranitidine.

 

The survey studied which medicine would healthcare providers prescribe in place of ranitidine, due to the sales suspension on ranitidine products.

 

1,664 doctor members of the online community, who prescribes ranitidine, participated in the latest survey.

 

33.4 percent, 20.7 percent, 4.4 percent, 3.6 percent, and 3.6 percent of survey participants were from internal medicine, family medicine, neurology, surgical, and dermatology departments, respectively.

 

Apparently, the overall 796 doctors are prescribing ranitidine for about ten patients a day.

 

The study found the most number of doctors (48.7 percent) are considering on prescribing PPI instead of ranitidine, and other options like H2RA (35 percent) and mucosal protective agent (15.1 percent) followed.

 

On a questionnaire confirming doctor’s preference order of single agent treatment alternative to ranitidine, 82.9 percent of survey participants ‘agreed’ with the order of ‘PPI, H2RA and mucosal protective agent’ as preferred options in the order.

 

Among the group of doctors who chose PPI for an alternative option, 70.6 percent of them particularly picked esomeprazole as their primary option in mind.

 

Lansoprazole (11.6 percent), rabeprazole (9.8 percent) and pantoprazole (8 percent) followed the list of preferred options of PPI.

 

43.2 percent of the group of doctors who chose H2RA answered they are contemplating on famotidine, and others chose lafutidine (29 percent), cimetidine (14.9 percent) and nizatidine (12.9 percent), in the order of preference.

 

The survey also reported doctors’ preference order of mucosal protective drug was rebamipide (64.5 percent), artemisia asiatica medicine (27.1 percent), sucralfate (4.4 percent) and bismuth (4.0 percent).

 

As for ranitidine combination therapy, 40.6 percent of doctors answered ‘combination of esomeprazole and Mosapride’, and other combinations of ‘esoeprazole and rebamipide (27.2 percent)’, ‘famotidine and rebamipide (18.5 percent)’ and ‘famotidine and Mosapride (13.6 percent)’ followed the list.

 

86.4 percent of the survey participants said they ‘agree’ on top three preferred prescription option of alternative ranitidine combination therapy to be ‘PPI and mucosal protective agent,’ ‘PPI and PKT’ and ‘H2RA and mucosal protective agent’, in the respective order.

 

On the other hand, 58.2 percent of doctors said the most crucial factors affecting ranitidine-alternative option are ‘acid blocking and mucosal protective effects,’ and other 18.2 percent of doctors said ‘safety’.